Colitis Pipeline Review, H1 2017 [Updated: 28022017] Prices from USD $2000

07:57 EDT 21 Apr 2017 | BioPortfolio Reports

Colitis Pipeline Review, H1 2017


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis Pipeline Review, H1 2017, provides an overview of the Colitis Gastrointestinal pipeline landscape.

Colitis is swelling inflammation of the large intestine colon. Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders ulcerative colitis and Crohn's disease, lack of blood flow ischemic colitis, past radiation to the large bowel. Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes nonsteroidal antiinflammatory drugs NSAIDs and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colitis Gastrointestinal, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis Gastrointestinal pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Colitis Gastrointestinal pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis Gastrointestinal.
The pipeline guide reviews pipeline therapeutics for Colitis Gastrointestinal by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA other developmental activities.
The pipeline guide reviews key companies involved in Colitis Gastrointestinal therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Colitis Gastrointestinal therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Colitis Gastrointestinal

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective RD strategies.
Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Colitis Gastrointestinal.
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Colitis Gastrointestinal pipeline depth and focus of Indication therapeutics.
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.

Original Article: Colitis Pipeline Review, H1 2017 [Updated: 28022017] Prices from USD $2000


More From BioPortfolio on "Colitis Pipeline Review, H1 2017 [Updated: 28022017] Prices from USD $2000"

Quick Search

Relevant Topic

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...